Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis  by Altman, R.D. et al.
OsteoArthritis and Cartilage (2005) 13, 13e19
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
doi:10.1016/j.joca.2004.10.012
International
Cartilage
Repair
SocietyTotal joint replacement of hip or knee as an outcome
measure for structure modifying trials in osteoarthritis
R. D. Altman M.D.a, E. Abadie M.D.b, B. Avouac M.D.c, G. Bouvenot M.D.d, J. Branco M.D.e,
O. Bruyere Ph.D.f, G. Calvo M.D.g, J.-P. Devogelaer M.D.h, R. L. Dreiser M.D.i,
G. Herrero-Beaumont M.D.j, A. Kahan M.D.k, G. Kreutz M.D.l, A. Laslop M.D.m,
E. M. Lemmel M.D.n, C. J. Menkes M.D.o, K. Pavelka M.D.p, L. Van De Putte M.D.q,
L. Vanhaelst M.D.r and J.-Y. Reginster M.D.*
On behalf of the Group for Respect of Excellence and Ethics in Science (GREES)
aRheumatology and Immunology, David Geffen School of Medicine at UCLA,
Los Angeles, CA, USA
bDepartment of Registration and Clinical Studies, French Agency For the
Safety of Health Products (AFSSAPS), France
cDepartment of Rheumatology, Henri Mondor Hospital, F-94010 Creteil, France
dDepartment of Clinical Trials Methodology, Faculte´ de Me´decine,
F-13385 Marseille Cedex 5, France
eUnidade Reumatologia, Hospital Egas Moniz, Lisbon, Portugal
fWorld Health Organization Collaborating Center for Public Health
Aspects of Rheumatic Diseases, Department of Public Health, Epidemiology
and Health Economics, University of Liege, Belgium
gDepartment of Clinical Pharmacology, Santa Creu, Sant Pau Hospital,
Autonomous University of Barcelona, Spain
hRheumatology Unit, UCL 5390, St-Luc University Hospital, Universite´
catholique de Louvain, B-1200 Brussels, Belgium
iDepartment of Rheumatology, Bichat Hospital, 75/018 Paris, France
j Department of Rheumatology, Madrid, Spain
kUniversite´ de Paris V, AP-HP, Hoˆpital Cochin, Paris, France
l BfArM, ARM, Bonn, Germany
mDepartment of Pharmacology, University of Innsbruck, A-6020 Innsbruck, Austria
nMax Grundig Klinik, Innere Medizin/Rheumathology, Bu¨hl, Germany
oUniversity Rene´ Descartes, Paris V, France
pDepartment of Medicine and Rheumatology, Charles University, Prague, Czech Republic
qDepartment of Rheumatology, University Medical Center Nijmegen, The Netherlands
r Department of Pharmacology, University of Brussels (VUB), Brussels, Belgium
Summary
Objective: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to
joint surgery as a potential therapeutic failure outcome criterion for osteoarthritis (OA) of the hip or knee in the assessment of potential
structure modifying agents.
Methods: PubMed was searched for manuscripts from 1976 to 2004. Relevant studies were discussed at a 1-day meeting.
Results: There are no accepted guidelines for ‘time to’ and ‘indications for’ joint replacement surgery. A limited number of trials have examined
joint replacement surgery within the study population. Several parameters, particularly joint space narrowing (interbone distance), correlate
with surgical intervention. However, at the level of the knee, none of the parameters have positive predictive value for joint replacement
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14 R. D. Altman et al.: Time to joint replacement therapysurgery better than 30%. In contrast, lack of signiﬁcant joint space narrowing has a strong negative predictive value for joint replacement
surgery (O90%), that remains after controlling for OA pain severity.
Conclusion: At this time, GREES cannot recommend time to joint surgery as a primary endpoint of failure for structure modifying trials of hip or
knee OAeas the parameter has sensitivity but lacks speciﬁcity. In contrast, in existing trials, a lack of progression of joint space narrowing has
predictive value ofO90% for not having surgery. GREES suggests utilizing joint space narrowing (e.g.,O0.3e0.7 mm) combined with a lack
of clinically relevant improvement in symptoms (e.g., R20e25%) for ‘failure’ of a secondary outcome in structure modifying trials of the hip
and knee.
ª 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Joint space narrowing.Introduction
Until recently, therapy of osteoarthritis (OA) has been
directed at symptoms, primarily pain. There is a concerted
effort to study new and established agents for their potential
to alter the course of OA1,2. Regulatory agencies have
recognized that there is a potential for an agent to interfere
with the structural progression (disease modiﬁcation) of
OA3,4. To date, a variety of surrogate outcome criteria have
been examined for hip and knee OA including markers of
cartilage and/or bone metabolism and imaging of joint
space narrowing (interbone distances)1,5.
Although joint space narrowing on a standardized radio-
graph is an appropriate primary endpoint, it is apparent to
the regulatory agencies that a reliable clinical endpoint
would be more desirable. Development of potential struc-
ture modifying agents has been hampered by the lack of
a generally accepted and validated clinical outcome to ﬁll
this role.
Prevention, or delay, to joint replacement surgery is an
attractive outcome measure of clinical disease progression
(Table I). We address the potential utility of ‘time to joint
replacement’ as a variable in the measurement of pro-
gression of OA of the hip or knee.
Table I
Lower extremity joint surgery as an outcome in structure modifying
trials of osteoarthritis of the hip or knee
Joint replacement as an attractive outcome criteria
Large numbers of surgical procedures
Patients opt to non-surgical interventions
Financial burden of surgery and rehabilitation
Risk of general surgery
Factors that may predispose to total joint replacement
Advancing age
WomenOmen
Severe pain
Disability (e.g., Algofunctional index)
Progressive joint space narrowing (interbone distance) on
radiography
Factors inﬂuencing the time to performing joint replacement surgery
Regional variations6,7
Women more than men6,7
Related to population density6
Lack of correlation to number of surgeons6
Tend to dependency on demographics (e.g., income, sex, age,
race)7
Health policy
Level of pain
Level of disability
Inequity in waiting times8
Insurance carrier vs single carrier insurance vs out of pocket
payment
Rationing by Health Maintenance Organizations9Method
The Group for the Respect of Ethics and Excellence in
Science (GREES) ‘‘Section Osteoarthritis’’, met on March
12, 2004. The GREES includes academic scientists with an
extensive background in the considered ﬁeld (i.e., rheuma-
tology, public health, radiology, biochemistry, epidemiology
and health economics), members of European national
regulatory authorities and representatives of the pharma-
ceutical industry. A subgroup of the GREES (BA, OB, J-YR)
performed an extensive search of the Medline electronic
database from 1977 until 2004. Keywords included ‘‘in-
dication for total joint replacement’’, ‘‘time to total joint
replacement’’, ‘‘outcome in osteoarthritis’’. In addition, Med-
line was searched by the names of several prominent clinical
research investigators with an interest in outcome in OA.
Since not all data are indexed in the electronic databases,
we conducted a hand search of the reference section of
each of the articles retrieved by the primary search until no
new paper was found. We also contacted GREES members
(scientists or industrial partners) active in OA. The invited
experts made a critical analysis of the available science. The
objective was to provide regulatory authorities with a refer-
ence on their evaluation of guidelines for registration of
agents for therapy of structure modiﬁcation in OA.
Manuscripts were screened for indications for ‘total joint
replacement’ and ‘time to joint replacement surgery’. The
search was limited to the hip and knee. Only English
language manuscripts were reviewed.
Results
CURRENT REGULATORY GUIDELINES
Existing regulatory guidelines for the approval of drugs to
be used as structure modifying drugs for the treatment of
OA have been published in the United States and in
Europe3,4. The US FDA guidelines state that ‘time to joint
surgery’ is an acceptable outcome for structure modifying
drugs3. Similarly, the European Committee for Proprietary
Medicinal Products (CPMP) guidelines state that even
though a structure modifying drug may not have an
independent effect on symptoms, clinical signs and
symptoms need to be assessed4. Hence, both United
States and European guidelines encourage delay in ‘time to
joint surgery’ to be examined in clinical trials of structure
modifying drugs.
OUTCOMES OF RECENT CLINICAL TRIALS WITH STRUCTURE
MODIFYING DRUGS
A limited number of clinical trials have examined the
relationship of ‘time to joint surgery’ as an outcome
parameter10,11. These publications report the results
15Osteoarthritis and Cartilage Vol. 13, No. 1obtained after treatment of hip or knee OA patients with
diacerein and glucosamine sulphate.
Several but not all12 clinical studies demonstrate the
clinical effectiveness of glucosamine sulphate in OA,
particularly of the knee. Two 3 year studies demonstrated
a reduction on joint space narrowing of the medial
compartment of the knee when comparing glucosamine
sulphate to placebo treated patients (Tables II and III)13,14.
A 5 year follow-up was conducted to assess long-term
outcomes after treatment discontinuation, including the
occurrence of OA-related joint surgery, evolution of
radiographic knee joint structure changes and symptoms,
quality of life and the pharmacoeconomic impact on the use
of health resources11. Patients on glucosamine sulphate for
3 years had a signiﬁcantly smaller radiographic joint space
narrowing and still exhibited an improvement on pre-trial
scores of the Western Ontario McMaster Universities
Osteoarthritis Index (WOMAC) Algofunctional index at the
5 year follow-up. Finally, quality of life Short Form (SF)-36
scores were better in the glucosamine sulphate treated
patients. A pharmacoeconomic questionnaire suggested
that the glucosamine sulphate treated patients used fewer
health resources during the previous year.
Diacerein may be an interleukin (IL)-1b inhibitor. In
clinical trials, diacerein was shown to reduce pain and
functional impairment in patients with hip or knee OA
(Tables IV and V)15. In the 3 year Evaluation of the
Chondromodulating Effect of Diacerein in Osteoarthritis of
the Hip (ECHODIAH) study10, diacerein was evaluated for
Table II
Glucosamine sulphate structure modifying trial follow-up11,13
Subsets Placebo Glucosamine Total
3 year
trial (N )
106 106 212
5 year follow-up (N )
Died 8 12 20
Lost to follow-up 12 3 15
Clinic follow-up 43 58 101
5 year follow-up
Lower limb OA-related surgery (N )
Any surgery hip or kneey 17 9 26
Any surgery kneez 14 8 22
TJRx 12 7 19
TJRZ total joint replacement hip or knee.
yRR 0.52; PZ 0.06.
zRR 0.54; PZ 0.13.
xRR 0.55; PZ 0.18.its effect on the progression of joint space narrowing in
patients with hip OA. The study achieved three of the four
primary endpoints that measured radiographic progression
of hip OA. Although there was no difference in mean joint
space narrowing for the intent-to-treat population between
diacerein and placebo, there was signiﬁcantly less pro-
gression in mean joint space narrowing for the complete
analysis. In addition, there were signiﬁcantly fewer patients
with radiographic joint space narrowing of at least 0.5 mm at
any time during the study period when comparing diacerein
treated patients to those on placebo. In relation to total hip
replacement (THA) surgery, there was a trend towards
fewer patients undergoing THA procedures in the diacerein
group when compared to the placebo group.
CRITERIA FOR TOTAL JOINT REPLACEMENT
Despite the success of total joint replacement of the hip
and knee over the last 30C years, the criteria for when to
perform such surgery are not clear. THA is an option for
nearly all patients with diseases of the hip that cause
chronic discomfort and/or signiﬁcant functional impair-
ment16. At a National Institutes of Health sponsored
workshop, the following statement was issued: ‘‘NIH
Consensus Statement concluded that candidates for THA
should have moderate to severe persistent pain, disability,
or both, not substantially relieved by an extended course of
non-surgical management in association with radiographic
signs of OA’’16e18.
The level of pain needed to indicate surgery is
appropriate is unclear. In two Canadian pre-operative
evaluations of 188 and 163 patients with hip OA, the
average mean WOMAC pain subscale scores by visual
analog scale (VAS) were 53G 17SD mm and
57G 16 mm19,20. The day before THA the mean WOMAC
pain subscale score was 55G 17 mm in 74 patients from
Sweden21. In the Netherlands, 62 patients averaged
63G 25 mm in a VAS pain score while waiting for THA22.
Similar results were obtained in the ECHODIAH study
where the mean VAS was 56G 17 mm prior to surgery in
135 patients undergoing THA (Table IV). Although these
numbers appear reasonably consistent, many patients were
on analgesic and/or anti-inﬂammatory drugs. In addition,
there is no separation in the level of pre-operative pain for
those undergoing joint replacement surgery and the level of
pain in the majority of reported clinical trials for those who
do not have immediate plans for joint replacement surgery.
A United Kingdom study evaluated the relationship of
disability to joint replacement study of 249 patients in
the post-operative period. They found that pre-operativelyTable III
Joint space narrowing as a predictor of knee surgery in glucosamine sulphate 5 year follow-up11,13
JSN (mm) Prevalence
(%)
RR
(95% CI)
P Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Overall
efﬁcacy (%)
R 0.2 42 3.01 (1.09e8.26) 0.03 63 60 19 92 62
R 0.3 40 3.43 (1.24e9.53) 0.017 63 64 20 92 66
R 0.4 37 3.88 (1.39e10.86) 0.009 63 67 22 93 69
R 0.5 32 4.61 (1.65e12.84) 0.003 63 73 25 93 73
R 0.6 29 5.16 (1.76e15.12) 0.003 61 76 28 93 77
R 0.7 26 5.15 (1.70e15.60) 0.004 63 79 30 94 79
R 0.8 24 4.83 (1.64e14.20) 0.004 50 80 27 92 78
Adjusted for age, body-mass index, total WOMAC, baseline minimal JSW. JSNZminimal joint space narrowing; RRZ relative risk; PZP
value; PPVZ positive predictive value or percent ability of JSN to predict knee surgery; NPVZ negative predictive value or the lack of the
ability of JSN to predict knee surgery.
16 R. D. Altman et al.: Time to joint replacement therapy62% were handicapped but independent and 26% were
partially dependent23. The WOMAC physical function
subscale averaged 60G 16SD mm in 188 Londoners,
61G 15SD mm in 163 Canadians, and 61G 15SD mm in
74 patients from Sweden19e21. The mean Lequesne
Algofunctional Index just prior to THA in 126 patients from
the ECHODIAH study was 12.6G 4.3 mm (baseline values
from the overall ECHODIAH study were 9.2G 2.7 mm). In
a study of 72 patients undergoing THA from the United
States, 79% had lost R50% of their functional capacity
between the beginning of symptoms to the time of
surgery24. These latter studies record change in function
prior to surgery, but no amount of change was proposed
to suggest the need for or indication of surgery. In the
ECHODIAH study, the higher baseline values for sym-
ptoms were strongly correlated with total joint arthroplasty
(P! 0.0001)25.
The overall clinical severity of OA examined in 2124
patients undergoing THA was 56 mm (average) in the total
WOMAC from the United Kingdom Hip and Knee Regis-
ter26. In the ECHODIAH study, both change in VAS for pain
and worsening Lequesne Algofunctional Index predicted
the occurrence of surgery25.
Global scores for the indication for THA have been
proposed, but limited validation has been published27e29.
It appears that there is considerable variation in the time
to surgery among surgeons. Time to surgery is inﬂuenced
Table IV
Total hip arthroplasty (THA) in patients within 6 months of
completion of a 3 year trial of diacerein10
CTHA
(nZ 135)
THA
(nZ 372)
t-Test
(P value)
VAS pain (mm)
Mean (SD) 55.8 (17.5) 33.7 (18.4) !0.0001
Maximum (SD) 79.4 (15.8) 59.4 (20.1) !0.0001
Algofunctional index (0e24)
Mean (SD) 9.2 (2.7) 6.0 (2.6) !0.0001
Maximum (SD) 13.6 (3.5) 9.3 (2.9) !0.0001
Algofunctional index
R 12 (N ) 95 68
!12 (N ) 40 304
VAS handicap (mm)
Mean (SD) 55.5 (19.1) 32.6 (19.4) !0.0001
Maximum (SD) 81.4 (15.9) 61.5 (22.5) !0.0001
Narrowest joint
space width
Mean (SD) 1.23 (0.8) 2.18 (0.9) !0.0001
Maximum (SD) 0.69 (0.9) 1.84 (1.0) !0.0001
CTHAZ Total hip arthroplasty performed; THAZ Total hip
arthroplasty not performed; Algofunctional index of Lequesne (see
text).
Table V
Predictive values for total hip arthroplasty in patients within 6
months of completion of a 3 year trial of diacerein10
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
VAS pain R 70 mm 78 66 45 89
Algofunctional index R 12 70 82 58 88
VAS handicap R 70 mm 79 56 40 88
Narrowest joint
space width% 1 mm
73 74 51 88by many factors (Table I), and variation exists between
countries, cities within countries, and surgeons within the
same institution. The rate of hip replacement surgery
increases with age until age 75, when it declines30. Women
and whites had higher rates of THA than men and
AfricaneAmericans.
There has been a recent appreciation of the predictive
value of high signal bone marrow lesions (previously called
bone edema) with the progression of OA of the knee31.
Additional studies are needed to determine the sensitivity
and speciﬁcity of this ﬁnding in predicting joint replacement
surgery.
Several groups have been formed in an attempt to set up
criteria to determine when joint replacement surgery would
be indicated27e29,32,33.
JOINT SPACE WIDTH AS A CRITERION FOR JOINT
REPLACEMENT SURGERY
A retrospective analysis of knee OA examined the
outcome of 1507 patients with serial extended weight
bearing knee radiographs34. They deﬁned patients as
a ‘failure’ if they reached a rating of 3 for joint space width
using an atlas of radiographs. The KaplaneMeier survival
analysis used time to reach the rating of 3 from baseline.
They also rated a ‘failure’ if the patient underwent total joint
replacement; they then combined the two ‘failure’ groups. In
COX regression analysis, initial joint space width, body-
mass index (BMI), symptom duration and global severity
were predictors of progression. The strongest predictor of
‘failure’ was reduced baseline joint space width, even after
adjustment for pain.
A study of 423 patients followed for 5 years evaluated
decrease in joint space width. For years 1 and 2 there was
a reduction of 0.2 and 0.4 mm, with a relative reduction of
15 and 20%, respectively. This resulted in a prediction of
THA speciﬁcity of 67e68% and sensitivity of 68e75%35.
CLINICAL TRIALS THAT HAVE EXPLORED TIME TO SURGERY
A limited number of studies have examined time to
surgery as a criterion for effectiveness of a structure
modifying drug10,11.
Glucosamine sulphate was studied in two 3 year clinical
trials for structure modiﬁcation13,14. As above, one of the
trials has a 5 year follow-up available that examines
symptoms, quality of life, the pharmacoeconomic impact
on use of health resources, radiographic knee joint
structural changes and the occurrence of OA-related joint
surgery (Tables II and III)11. Of the original 212 patients with
knee OA, 177 (83%) could be contacted and queried about
their arthritis (Table II). Lower limb surgery was performed
on 27 patients with total knee or hip surgery performed in 19
(Table III). Despite small numbers, there was a trend toward
a difference between those on placebo vs glucosamine
sulphate for lower limb OA-related surgery (PZ 0.06).
Reduction in minimum joint space width and sex (women)
were predictors of the need for joint surgery in two models
of logistic regression (PZ 0.004e0.007). The model
includes minimal joint space width at baseline with BMI,
age, total WOMAC, change in total WOMAC, pain subscale
of the WOMAC and change in pain subscale of the
WOMAC. The overall efﬁciency of minimal but not mean
joint space narrowing to predict those going to surgery is
demonstrated in Table III. Although the relative risk, P
values and predictive values suggest progressive reduction
17Osteoarthritis and Cartilage Vol. 13, No. 1Table VI
Joint space narrowing with pain as a predictor of knee surgery in glucosamine sulphate 5 year follow-up11,13
JSN painy
(mm)
Prevalence
N (%)
RR
(95% CI)
P Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Overall
efﬁcacy (%)
R 0.5 69/122 (54) 4.99 (1.18e21.18) 0.012 87 48 19 96 55
R 0.7 66/122 (54) 5.52 (1.30e23.41) 0.007 87 50 20 96 57
Adjusted for age, body-mass index, total WOMAC, baseline minimal JSW. JSNZminimal joint space narrowing; RRZ relative risk; PZP
value; PPVZ positive predictive value or percent ability of JSN to predict knee surgery; NPVZ negative predictive value or the lack of the
ability of JSN to predict knee surgery.
yPainZ improvement of %20% in WOMAC pain subscale.in minimal joint space narrowing is predictive of those going
to joint surgery for the knee, the speciﬁcity is lost with the
predictive value not higher than 30%.
Further analysis of the two glucosamine sulphate studies
allows combining symptom response with joint space
narrowing (Table VI)13,14. For a failure deﬁnition of joint
space narrowing of R0.5 mm and !20% improvement in
the WOMAC pain subscale of 20%, there would be 55/133
(41%) failures with glucosamine sulphate vs 74/124 (60%)
on placebo (PZ 0.003).
The ECHODIAH trial was a 3 year, multicenter, pro-
spective study designed to evaluate the structural effect of
diacerein vs placebo on OA of the hip. Patients were
evaluated every 3 months and radiographs were obtained
yearly. A post-hoc analysis examined those undergoing
THA within 6 months of completion of the 3 year study. This
was compared with those not undergoing THA in the same
time period (Tables IV and V). Although the negative
predictive values were near 90%, the best positive pre-
dictive value was the Lequesne Algofunctional index of
R12 at 58%econsistent with the above glucosamine
sulphate study results.
Discussion
Although attractive as a ‘‘hard’’ clinical outcome for the
failure of drug in a structure modifying trials for OA of the hip
and knee, time to joint surgery as a variable has been
hampered by inconsistency in the decision on when to
perform surgery, the lack of standardized guidelines for
when to perform surgery and the lack of adequate number
of studies that examine joint surgery as an endpoint in
structure modifying trials. Hence, GREES is reluctant to
recommend ‘time to joint surgery’ as a primary endpoint for
OA of the hip and knee extremity surgery until there is
additional data validating this method.
However, at this time, the speciﬁcity and sensitivity of
existing data suggest that criteria, such as lack of pro-
gressive joint space narrowing is predictive of not going to
surgery. The negative predictive value of this outcome is
over 90% for any of the selected cutpoints between 0.3 and
0.7 mm in the glucosamine sulphate studies.
There have been several attempts to develop guidelines
for when to perform joint replacement surgery. Few are
supported by research. Support for the negative predictive
value of a variety of measurements for joint replacement is
from a study on a composite index for THA29. The group
studied 466 patients with clinical and radiographic data.
Their composite index had a positive predictive value of
54% and a negative predictive value of 87%. They
concluded that the index was of value in selecting those
patients who should not be referred for THA.There are a variety of issues not raised by the existing
clinical trials. Clinical trialseby designehave selected
populations, and probably do not reﬂect the general
population. Some of the issues are noted:
 Differences in the design of clinical trials tend to select
different populations of patients: e.g., a structure
modifying trial would tend to include less severely
symptomatic patients than a short-term anti-inﬂamma-
tory agent trial.
 Time to joint replacement may be different in these two
populations. Since there are no generally accepted
criteria for joint replacement surgery, patients entering
the trial may already be candidates for joint replacement
surgery; hence, going to surgery during the trial
introduces bias. Conversely, patients entering a long-
term structure modifying trial may be doing so with a very
strong desire (more than the usual) to avoid surgery.
 The majority of patients with OA do not progress very
rapidly to joint replacement surgery, increasing the
sample size required to demonstrate a difference
between therapy and placebo.
 There is a subset of patients with a rather rapid
progression of OA that will come to surgery more
quickly than the overall study population. At present,
there are no clinical markers to identify this population
at the onset of the trial.
 Patients are generally selected on the basis of Kellgren
Lawrence grade II or III. At present, there is no good
clinical correlation to the pathologic ﬁndings with these
classiﬁcations. They probably represent a variety of
populations that may or may not respond to the same
therapy.
 There are differences in the progression of OA in hip
and knee. Will a structure modifying agent have an
equal effect on delaying surgery in these two groups?
Will separate studies need to be conducted?
The multiple complicating factors that inﬂuence time to
joint surgery have not been adequately separated and
studied. New studies on structure modifying agents need to
include time to joint surgery as a secondary efﬁcacy
parameter for failure of the study drug in order to develop
a better understanding of the relevance of this observation.
At this stage, the GREES recommends that ‘failure’ as a
secondary endpoint be included in clinical trials of structure
management of OA of the lower limbs. ‘Failure’ is deﬁned
as an individual developing progression of minimal joint
space narrowing (threshold over a minimal of 0.3 and
0.7 mm) and without a clinically relevant symptomatic
beneﬁt (i.e., 20e25% improvement on the WOMAC pain
subscale).
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